Tim Petersen
Founder and Managing Partner @ Arboretum Ventures
Detroit, United States
Tim Petersen is a funding round investor at Arboretum Ventures in Detroit focused on Health Care and Medical Device. Tim Petersen is based out of Ann Arbor, Michigan and is the Managing Partner, Founder of Arboretum Ventures. Tim previously worked at Pear Therapeutics as a Board Member. Tim Petersen attended the University of Michigan - Stephen M. Ross School of Business.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Tim Petersen invests in
Stages Tim Petersen invests in
Countries Tim Petersen invests in
Investment Focus
Industry
- Health Care 9 (53%)
- Medical Device 5 (29%)
- Medical 4 (24%)
- Biotechnology 4 (24%)
- Hospital 3 (18%)
Stage
- Funding Round 4 (24%)
- Series A 3 (18%)
- Series C 2 (12%)
- Series E 2 (12%)
- Seed 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ViaLase
|
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. The company's system focuses on the development of micron-resolution OCT image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to theSchlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment.ViaLase was incorporated in 2019 and is headquartered in Corona Del Mar, California. | $40M / Series C / Apr 01, 2024 | |
Convergent Dental
|
Convergent Dental is a privately-owned dental equipment and technology company developing a computer-aided dental preparation system designed to offer a comfortable patient experience during dental surgeries. It is a carbon-dioxide laser for both hard and soft tissue indications that cuts quietly, finely, and faster than other laser-based systemsin dentistry using patented technologies and computer system controls. | $5M / Venture - Series Unknown / Apr 24, 2023 | |
Navv Systems
|
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multipleU.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs. | $5.5M / Series A / Sep 02, 2022 | |
|
Convergent Dental
|
Convergent Dental is a privately-owned dental equipment and technology company developing a computer-aided dental preparation system designed to offer a comfortable patient experience during dental surgeries. It is a carbon-dioxide laser for both hard and soft tissue indications that cuts quietly, finely, and faster than other laser-based systemsin dentistry using patented technologies and computer system controls. | $40M / Series C / Oct 29, 2021 | |
|
Navv Systems
|
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multipleU.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs. | $3.2M / Seed / Jun 06, 2021 | |
Intellicyt
|
IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells andbeads. IntelliCyt’s products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences.Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyt’s HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost. | $7.4M / Oct 22, 2015 | |
My Health Direct
|
My Health Direct operates as a health services solutions company that connects hospitals, care management organizations, public agencies, and community collaboratives for the purpose of scheduling and booking healthcare appointments on behalf of individuals. It offers a Web-based solution that organizes and books open and available healthcareappointments in the community into a searchable and schedulable inventory of healthcare services. My Health Direct, Inc. was formerly known as Global Health Direct.The company was founded in 2005 and is based in Brookfield, Wisconsin. | $8M / Oct 08, 2014 | |
|
Intellicyt
|
IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells andbeads. IntelliCyt’s products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences.Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyt’s HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost. | $8M / May 06, 2013 | |
Tangent Medical Technologies
|
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenouscatheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCathâ„¢ Closed IV Catheter System, in 2012. | Series B / Nov 14, 2012 | |
|
Tangent Medical Technologies
|
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenouscatheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCathâ„¢ Closed IV Catheter System, in 2012. | Jun 25, 2012 | |
| See all 17 investments → | |||
Co-Investors
Chrysalis Ventures
5 deals together
OUP (Osage University Partners)
3 deals together
Detroit Venture Partners
2 deals together
Narrow Gauge Ventures
2 deals together
Ares Capital
1 deal together
Baird Capital
1 deal together
About Arboretum Ventures
Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.
Arboretum Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul McCreadie
Managing Partner and Chief Operating Officer
|
|||
Robert Cesaro
Associate
|
|||
|
Tim Petersen
Founder and Managing Partner
|
|||
Amanda Goldstein
Executive Assistant
|
|||
George Dunbar
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Tim Petersen invest in?
Tim Petersen invests primarily in Health Care, Medical Device and Medical startups, most often at Funding Round and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Tim Petersen last invest?
The most recent investment recorded for Tim Petersen closed in Apr 2024. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
